The URPL website has published a message addressed to professional health care workers on the obstruction of access to a medicinal product. What drug is it about?
The drug in question is liraglutide 6 mg/ml, solution for injection in a pre-filled injector. The Polish representative of the drug's manufacturer informed "that due to the fact that both in Poland and globally we are facing an unprecedented and dynamically growing demand for the drug from the GLP-1 analogue group appearing under the trade name: Saxenda (liraglutide, 6 mg/ml, solution for injection in a pre-filled injector)...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
